公开(公告)号：US20080124308A1

公开(公告)日：2008-05-29

申请号：US11632302

申请日：2005-07-14

申请人： M. Dorothee Laer ,  Hrvoje Miletic ,  Yvonne Fischer

发明人： M. Dorothee Laer ,  Hrvoje Miletic ,  Yvonne Fischer

IPC分类号： A61K35/00 ,  A61P43/00

CPC分类号： A61K38/2026 ,  A61K9/5068 ,  A61K38/18 ,  A61K38/45 ,  A61K38/50 ,  A61K48/00 ,  C12N15/86 ,  C12N2740/15032 ,  C12N2740/15043 ,  C12N2740/15045 ,  C12N2740/15052 ,  C12N2760/10022 ,  C12N2810/6072 ,  A61K2300/00

摘要： The present invention concerns the use of packaging cells which produce retroviral virions pseudotyped with arenavirus glycoprotein, for the manufacture of a pharmaceutical composition for the gene therapy of solid tumors. The invention further concerns the use of the virions which are produced by these packaging cells, for the manufacture of a pharmaceutical composition for the gene therapy of solid tumors. Furthermore, packaging cells which are suitable for this application and pharmaceutical compositions containing these cells are subject matter of the invention.

摘要翻译： 本发明涉及使用产生用斑马鱼病毒糖蛋白假型分离的逆转录病毒体的包装细胞，用于制造用于实体瘤基因治疗的药物组合物。 本发明还涉及由这些包装细胞产生的病毒粒子用于制造用于实体瘤基因治疗的药物组合物的用途。 此外，适用于本申请的包装细胞和含有这些细胞的药物组合物是本发明的主题。

公开(公告)号：US20060280754A1

公开(公告)日：2006-12-14

申请号：US10578013

申请日：2004-11-03

申请人： Robert Garry

发明人： Robert Garry

IPC分类号： A61K39/395 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K38/04 ,  A61K38/162 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C12N7/00 ,  C12N2760/10022 ,  C12N2760/14122 ,  C12N2760/18422 ,  C12N2760/18433 ,  C12N2770/20022 ,  C12Q1/18 ,  G01N33/56988

摘要： The present invention relates to a method of preventing or inhibiting viral infection of a cell and/or fusion between the envelope of a virus and the membranes of a cell targeted by the virus (thereby preventing delivery of the viral genome into the cell cytoplasm, a step required for. viral infection). The present invention particularly relates to the families of RNA viruses, including the arenaviruses, coronaviruses, filoviruses, orthomyxoviruses, paramyxoviruses, and retroviruses, having Class I membrane fusion proteins as the fusion proteins that mediate this fusion process. The present invention provides for a method of identifying a conserved motif or domain called the fusion initiation region (FIR) in these viruses. The present invention further provides for methods of preventing infection by such viruses, by interfering with their FIR. The present invention further provides for methods of treatment and prophylaxis of diseases induced by such viruses.

摘要翻译： 本发明涉及一种预防或抑制病毒感染病毒感染和/或病毒包膜与病毒靶向细胞膜（从而防止病毒基因组递送到细胞质中的融合物）的方法 病毒感染所需的步骤）。 本发明特别涉及RNA病毒家族，其包括具有I类膜融合蛋白作为介导该融合过程的融合蛋白的氨甲威病毒，冠状病毒，弧菌病毒，正粘病毒，副粘病毒和逆转录病毒。 本发明提供了鉴定这些病毒中称为融合起始区（FIR）的保守基序或结构域的方法。 本发明进一步提供了通过干扰它们的FIR来防止这种病毒感染的方法。 本发明还提供了治疗和预防由这些病毒引起的疾病的方法。

公开(公告)号：US20060210588A1

公开(公告)日：2006-09-21

申请号：US10550580

申请日：2004-03-25

申请人： Martin Bachmann ,  Adrian Huber ,  Vania Manolova ,  Edwin Meijerink ,  Karl Proba ,  Alain Tissot

发明人： Martin Bachmann ,  Adrian Huber ,  Vania Manolova ,  Edwin Meijerink ,  Karl Proba ,  Alain Tissot

IPC分类号： A61K39/21 ,  A61K48/00

CPC分类号： A61K39/21 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55561 ,  C07K2319/40 ,  C12N7/00 ,  C12N2710/22023 ,  C12N2710/22042 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2730/10142 ,  C12N2740/16034 ,  C12N2740/16222 ,  C12N2760/10022 ,  C12N2795/18122 ,  C12N2795/18123 ,  C12N2795/18142 ,  Y02A50/467

摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular HIV peptides linked thereto. Such CpG-VLPs are dramatically more immunogenic that their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against HIV peptides optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against HIV peptides are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含VLP的修饰病毒样颗粒（VLP），其可加载免疫刺激物质，特别是与含有非甲基化C和G（CpG）的DNA寡核苷酸以及与其连接的特定HIV肽。 这样的CpG-VLP显着地更具免疫原性，使其不含CpG的对应物并诱导增强的B和T细胞应答。 任何偶联，融合或附加到VLP的HIV肽的免疫应答相似地增强，因为针对HIV肽的免疫应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。

公开(公告)号：US20050123517A1

公开(公告)日：2005-06-09

申请号：US10993319

申请日：2004-11-19

申请人： Paul McCray ,  Beverly Davidson ,  Colleen Stein

发明人： Paul McCray ,  Beverly Davidson ,  Colleen Stein

IPC分类号： A61K48/00 ,  C07K14/08 ,  C12N5/10 ,  C12N15/867 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  C12N2740/15043 ,  C12N2740/15045 ,  C12N2760/10022 ,  C12N2810/6072

摘要： The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.

公开(公告)号：US06440730B1

公开(公告)日：2002-08-27

申请号：US09309572

申请日：1999-05-11

申请人： Meike-Dorothee Von Laer ,  Winfried Beyer

发明人： Meike-Dorothee Von Laer ,  Winfried Beyer

IPC分类号： C12N500

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  C12N2740/13043 ,  C12N2740/13045 ,  C12N2740/13052 ,  C12N2760/10022 ,  C12N2810/60

摘要： The present invention relates in general to the pseudotyping of retroviruses with lymphocytic choriomeningitis virus. In particular, the invention relates to pseudotyping in MLV packaging cells which are optionally env-deleted, or in packaging cells derived from lentiviruses. Preferably, pseudotyping takes place by infection with LCMV or a preferably env-deleted mutant, or by transfection with an expression plasmid containing the gp gene of LCMV or a part thereof and optionally, in addition, the np, 1 and/or the z gene of LCMV. The invention also relates to the use of such pseudotypes for the infection of cells, particularly the use in gene therapy.

摘要翻译： 本发明一般涉及具有淋巴细胞性脉络丛脑膜炎病毒的逆转录病毒的假型分型。 特别地，本发明涉及在任选缺失的MLV包装细胞中或在来源于慢病毒的包装细胞中的假型分型。 优选地，通过LCMV或优选缺失突变体的感染或通过用含有LCMV或其一部分的gp基因的表达质粒转染，并且任选地另外还包含np，1和/或z基因，进行假型分型 的LCMV。 本发明还涉及这种假型用于细胞感染的用途，特别是在基因治疗中的用途。